Arbutus to Participate in September Investor Conferences

Rhea-AI Summary

WARMINSTER, Pa., Sept. 06, 2022 – Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13 at 12:30 PM ET, with CEO William Collier as the presenter. Additionally, they will hold a fireside chat at Baird's 2022 Global Healthcare Conference on September 14 at 10:15 AM ET. Live webcasts will be available on their website, with replays accessible post-event.

WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York:

H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)

• Company Presentation: Tuesday, September 13^th at 12:30 pm ET
• Presenter: William Collier, President & Chief Executive Officer

Baird’s 2022 Global Healthcare Conference (September 13-14, 2022)

• Fireside Chat: Wednesday, September 14^th at 10:15 am ET
• Presenters: William Collier, President & Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Michael McElhaugh, Chief Business Officer; and David Hastings, Chief Financial Officer

Live webcasts of the presentation and fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to provide a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

What investor conferences will Arbutus Biopharma (ABUS) participate in September 2022?

Arbutus Biopharma will participate in the H.C. Wainwright 24th Annual Global Investment Conference and Baird's 2022 Global Healthcare Conference in September 2022.

What is the schedule for Arbutus Biopharma's presentations at the conferences?

The company will present on September 13 at 12:30 PM ET at the H.C. Wainwright Conference and will have a fireside chat on September 14 at 10:15 AM ET at Baird's Conference.

Who will be presenting for Arbutus Biopharma at the conferences?

William Collier, President & CEO, will present at the H.C. Wainwright Conference, while several executives including Collier will participate in the fireside chat at Baird's Conference.

How can I access the live webcasts of Arbutus Biopharma's presentations?

Live webcasts can be accessed through the Investors section of Arbutus Biopharma's website.

Will there be a replay of Arbutus Biopharma's presentations available?

Yes, an archived replay of the webcasts will be available on Arbutus Biopharma's website after the events.